Last month, we reported on the FSA crackdown with a brand new March 31st 2021 deadline for CBD companies to ensure they are legitimate.
Following this, 74% of respondents to a YouGov poll that was commissioned by the Association for the Cannabinoid Industry (ACI) backed the move. Of the 74%, 35% strongly supported the new rules.
Just 8% opposed the guidance – with 2% strongly opposed – while 18% remained undecided. Looking at these percentages, there is an “any cannabis is good cannabis” narrative from a health perspective, which has been proven to be not necessarily true when there is little to no CBD in some products at all. Also those pro blanket legalisation may not be fully aware of the ramifications for those who need the plant for medical purposes.
Recent research we published from the American Academy of Neurology showed that pharma-grade and specifically grown and tested cannabis is best for seizures. After next year’s deadline, only goods that have submitted a valid application will be allowed to remain on the market.
This week Veteran politician Frank Field became the first politician to reveal he was using medical cannabis and has hailed cannabis oil as a “wonder drug” – and told how he has spent thousands of pounds on a private prescription.
He said he turned to CBD – currently at the centre of a fierce debate in Parliament – to ease “crippling” pain from a slipped disc. Mr Field, who was an MP for 40 years, paid £2,200 for a three-month supply of Bedrolite, which you take by putting droplets on your tongue.
CBD product use has grown significantly in the UK within the past year, with recent research commissioned by the Centre for Medicinal Cannabis putting the value of the UK CBD market at £300m. It is forecast to grow to be worth more than £1bn by 2025.